Beatrice Benatti

2 papers in the library · publishing 2026

Papers

Sort Most recent Most cited

Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.

European Neuropsychopharmacology July 17, 2026 Allan H. Young, Bernhard T Baune, Beatrice Benatti et al.

Esketamine nasal spray (NS) is an established treatment for patients with treatment resistant depression (TRD). To further optimise real-world outcomes, consensus is needed regarding strategies to enhance patient outcomes and decision-making factors for pivotal timepoints in esketamine NS treatment. This modified Delphi panel (3 rounds) established expert consensus (≥80% agreement) from 30...

DOI: 10.1016/j.euroneuro.2026.112907 Full text Esketamine nasal spray Assessment patient outcome Decision-making shared Delphi method +1

Pilot study on esketamine response in treatment-resistant depression: impact of pharmacogenetic, clinical, and demographic variables.

Frontiers in Pharmacology 2026 Michaela Krivosova, Matteo Marcatili, Gessica Guerrera et al.

Esketamine, the S-enantiomer of ketamine, is a rapid-acting antidepressant approved for treatment-resistant depression (TRD) when used in combination with an oral antidepressant. Identifying reliable clinical or genetic predictors of treatment response remains a critical unmet need. This study aimed to evaluate the impact of selected clinical and genetic variables on esketamine response in a...

DOI: 10.3389/fphar.2026.1783538 Full text Esketamine Treatment-resistant depression Bdnf Cyp2b6 +4